Brief: Cymabay Therapeutics Announces Publication Of Results From The Enhance, Phase 3 Study Of Seladelpar In Patients With Primary Biliary Cholangitis (PBC)
21/04/2023 13:02
April 21 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* CYMABAY THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM
THE
ENHANCE, PHASE 3 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY
BILIARY CHOLANGITIS (PBC)
* CYMABAY - SELADELPAR IS CURRENTLY BEING EVALUATED IN
RESPONSE,
GLOBAL PHASE 3 REGISTRATION STUDY IN PATIENTS WITH PBC, EXPECTED
TO READ OUT IN Q3
Source text for Eikon: ID:nGNX1JHj6
Further company coverage: CBAY.O
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap